Cargando…
A novel mouse model for checkpoint inhibitor-induced adverse events
Immune checkpoint inhibitors have demonstrated significant efficacy in the treatment of a variety of cancers, however their therapeutic potential is limited by abstruse immune related adverse events. Currently, no robust animal model exists of checkpoint inhibitor-induced adverse events. Establishin...
Autores principales: | Adam, Kieran, Iuga, Alina, Tocheva, Anna S., Mor, Adam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877613/ https://www.ncbi.nlm.nih.gov/pubmed/33571254 http://dx.doi.org/10.1371/journal.pone.0246168 |
Ejemplares similares
-
PD-1-stimulated T cell subsets are transcriptionally and functionally distinct
por: Lerrer, Shalom, et al.
Publicado: (2021) -
Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors
por: Bukhari, Shoiab, et al.
Publicado: (2022) -
SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019) -
Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors
por: Wang, Zheng-Hang, et al.
Publicado: (2018) -
Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)